难以治疗的牛皮关节炎:迄今为止的道路
Angeliki E Dimopoulou1, Konstantinos D Vassilakis1, George E Fragoulis1
1Joint Academic Rheumatology Programme, First Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Mediterranean journal of rheumatology
|February 20, 2025
概括
定义难以治疗的牛皮关节炎 (D2T PsA) 对于改善患者的治疗结果至关重要. 目前的研究突出了D2T PsA定义的关键预测因素和挑战,指导未来的临床试验和治疗策略.
科学领域:
- 风湿病学和免疫学
- 皮肤病学 皮肤病学
- 内部医学 内部医学
背景情况:
- 牛皮关节炎 (PsA) 是一种复杂的免疫媒介疾病,具有多种肌肉骨和肌肉骨外表现.
- 尽管取得了进展,但很大一部分PsA患者无法获得令人满意的治疗结果.
- 难以治疗的牛皮关节炎 (D2T PsA) 的概念正在出现,反映了类风湿性关节炎的努力.
研究的目的:
- 审查关于D2T PsA的当前知识.
- 确定理解和定义D2T PsA. 的差距.
- 为推进D2T PsA概念提供考虑.
主要方法:
- 对D2T PsA现有的文献进行叙述性审查.
- 对D2T PsA.提出的定义和预测因素的分析.
- 讨论疾病活动测量和治疗耐火性标准方面的挑战.
主要成果:
- 拟议的D2T PsA定义各不相同,潜在的预测因素包括广泛的牛皮,轴参与,肥胖,女性性别和并发症 (IBD,抑郁症,纤维肌痛).
- 缺乏通用疾病活动指数和与时间相关的标准对D2T PsA定义构成挑战.
- 可能需要区分D2T PsA和耐火治疗的PsA.
结论:
- 定义D2T PsA对于改善临床试验,治疗策略和患者护理至关重要.
- 需要进一步的研究,以确定对D2T PsA的明确标准和验证措施.
- D2T PsA的概念需要进一步的细化和共识.
相关概念视频
01:26Psychosis: Goals of Pharmacotherapy
102
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
102
01:29Autoimmune Disorders
379
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
379
01:28Drug Therapy
35
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
35
01:29Inflammatory Bowel Disease IV: Pharmacological Management
95
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
95
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
135
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
135
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
145
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
145